Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
nice buys
Bl####y investors chronicle, was hoping to top up today with dividends elsewhere, still undervalued even at this price though
NB I think there may be a typo here:
"... I estimate the company now holds net cash of about £155m (124p a share), a sum that backs up two-thirds of its market capitalisation of £232m (171p)."
In the accompanying table we have:
"Proforma net cash at 28 January 2021 £155m 114.4p"
which squares with there being ~136m shares, and the "two-thirds" comment above.
So I think "124p" should have been "114p". Anyone agree/disagree?
Anyway, undervalued, but slightly less so today!
This morning's rise will be due to this - thanks to yellowdog on the advfn BB for spotting it :
https://www.investorschronicle.co.uk/ideas/2021/02/04/bargain-shares-for-2021/
(The Arix part starts about a third of the way down.)
Yes I read that, but still like to spend many hours, days researching before purchasing and I calculated 240p. Let's see on the 10th March
Scott - if you look at the link in jxck note about a week ago investors chronicle have this at 274p, taking cash out the investments at a deep c 67% discount.
Not if it's Acacia...
Been Buying last week, work out NAV to be around 240p. Look forward to results next month
Could it be that big seller has finished? No chunky sell offs today.
on the first spike to 180p. Bit gutted to see it fall back after I bought but now back to 180p official ask. Agree with the comments that this is way too cheap. Should be 220p to 240p imo. Buyers are plentiful today.
but caught on the spike to 180p. aving assessed the company and the research report plus the director buy I agree it is undervalued. If it falls to 165p I will be averaging down. The prospects look huge.
No spare cash, but at this level I might sell some long cherished investment trusts (bailee gifford, fidelity), this is just too cheap
Any ideas about the recent price drop?
Already heavily invested here, but at 180p wish I had some spare cash here.
Don't know why I was able to download this IC Alpha report on Arix for free, but here it is:
https://pdfs.investorschronicle.co.uk/IC_Alpha_Simon_283546.pdf..pdf
Some downturn in share price on this rns, clearly has been a key part of a team with the ability to pick winners.
A t c 200p the discount to nav must be very large, stripping out cash it is just ridiculous. Looking forward to updates.
The 50,000 deal at 14.51.26 is shown as a sell, but the spread at the time was 202-206, so it is more likely that the deal was actually a buy, being slightly above the middle price of 204.
This is a real expression of faith in the company.
But at this price of is backed by a significant backing of cash within arix, so downside is limited
Will the deal through will be really interesting to see the year end results. I particular level of cash, holdings valuation and movement and discount to nav (and discount to nav taking cash out).
I think my best stock this year.
Arix gets a mention in David Stevenson's Adventurous Investor column in the FT today
Amazing that investors rely so much on ST in the IC without question - price rise when they cannot have done any further research, incredible market influence this guy has, much of it unwarranted.
Thanks to pastybap on advfn for spotting this :
https://www.investorschronicle.co.uk/alpha/2020/12/11/exploit-this-biotech-investor-s-huge-margin-of-safety/
Today's RNS has obviously gone down well: SP is 195/200 as I type. Perhaps investors are wondering if Atox is the next in line for acquisition or JV?!
Link for the new Hardman report :
https://www.hardmanandco.com/wp-content/uploads/2020/12/ARIX-Artios-attracts-MerckKGaA-7-Dec-2020.pdf
"Investment summary: Two major deals in quick succession have demonstrated that ARIX has invested in interesting technologies that are attracting keen interest from the pharmaceutical majors. Having set itself some ambitious targets for the next three years, these deals suggest that the targets should be met comfortably, so the market should be narrowing the discount to NAV."
Lots of interesting comments on the Artios-Merck collaboration, e.g. :
"With the upfront payment and eight potential targets, each with potential milestones of up to $860m, the deal has a headline value of up to $7bn. In the event that just one or two of these targets is successful, in our opinion, Merck will face a decision about paying all the associated milestones to Artios, or simply take a view that it will be cheaper in the long term to buy the whole company."